secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001193125-24-238562
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.02, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar ends lupus trial after fatal SAEs, adopts poison pill to block $1.10 bid
------------------------------------------------------------------------------

- Discontinued PALIZADE Phase 2b in lupus nephritis after 4 Grade 5 SAEs (1 placebo); 84 patients enrolled.
- PORTOLA Phase 2a in autoimmune hepatitis continues; topline data due H1 2025.
- Board rejected Concentra's $1.10/share bid; adopted rights plan (10%/15% threshold, expires Oct 17, 2025).
- Preliminary cash ~$148M as of Sep 30, 2024; company says cash runway extended.
- Concentra accumulated 9.9% of KZR; grandfathered but cannot increase without triggering rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000119312524238562/0001193125-24-238562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000119312524238562/d881241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer